103522-34-5

Basic information

• Product Name: L-Phenylalanine, N-acetyl-2-chloro-
• CAS NO: 103522-34-5
• Molecular Formula: C11H12ClNO3
• Molecular Weight: 241.674
• Mol File: 103522-34-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: L-Phenylalanine, N-acetyl-2-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine, N-acetyl-2-chloro-(103522-34-5)
• EPA Substance Registry System: L-Phenylalanine, N-acetyl-2-chloro-(103522-34-5)

Safety Data

• Hazardous Substances Data: 103522-34-5(Hazardous Substances Data)

Upstream product

• 611-17-6 1-bromomethyl-2-chlorobenzene 
• 855650-84-9 acetylamino-(2-chloro-benzyl)-malonic acid 
• 5440-50-6 N-acetyl-3-(2-chlorophenyl)-2-ethoxycarbonyl alanine ethyl ester 
• 6955-12-0 (+/-)-N-acetyl-3-(2-chlorophenyl)alanine 
• 224186-21-4 2-(acetylamino)-3-(o-chlorophenyl)acrylate 
• 103616-89-3 (2S)-2-amino-3-(2-chlorophenyl)propanoic acid 

Downstream Products

• 103616-89-3 (2S)-2-amino-3-(2-chlorophenyl)propanoic acid 

Relevant articles and documents

Enantioselective borane reduction of prochiral ketones catalyzed by a chloro-containing chiral β-amino alcohol

A chloro-containing chiral β-amino alcohol (S)-2-amino-3-(2-chlorophenyl)-1,1-diphenyl-1-propanol (1) was prepared from the related amino acid, which was synthesized via malonic ester method. As a catalyst for the enantioselective borane reduction of prochiral ketones, 1 is better than those that have a similar structure but have no halogen atom in the molecule.

Highly enantioselective rhodium-catalyzed hydrogenation of dehydroamino acids with new chiral bisphosphinites

-

Novel atropisomeric bisphosphine ligands with a bridge across the 5,5′-position of the biphenyl for asymmetric catalysis

A new type of atropisomeric bisphosphine ligand 2 with a bridge across the 5,5′-position of the biphenyl has been developed. The axial chirality of this type of ligands can be retained by macrocyclic ring strain produced from 5,5′-linkage of the biphenyl

Endothelin antagonist

The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.